Ligand Pharmaceuticals

LGND

Market cap $4.45B

FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.

5,000 shares were sold on March 4, 2026, through an option exercise and immediate disposition, yielding a transaction value of ~$1.03 million at around $206.35 per share. The sale represented 11.94% of Reardon's direct holdings prior to the transaction, reducing his directly held common shares to 36,869.

A Ligand insider sold 3,057 shares of common stock on March 11, 2026, for $688,000. The transaction represented 12.70% of his direct common stock holdings, reducing his position from 24,067 to 21,010 shares.

JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments and Business Development.

Arecor Therapeutics PLC (AIM:AREC), the Cambridge-based biotech focused on diabetes and cardiometabolic treatments, has received a $500,000 commercial milestone payment from Ligand Pharmaceuticals under a royalty financing agreement struck in September 2025. The payment is the first milestone tranche under a deal in which Arecor sold Ligand the global royalty rights to AT220, an enhanced biosimilar insulin product, and related rights to AT292, a therapy licensed to Sanofi, in exchange for an initial $7 million upfront and up to $4 million in milestone payments.

Shares of Ligand Pharmaceuticals dropped into a sell zone Thursday, seemingly down in sympathy with the broader biotech segment.

Bank of America (BofA) Securities on Wednesday initiated coverage on Ligand Pharmaceuticals Inc (NASDAQ: LGND), citing the distinctive royalty firm offers compelling upside.

Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target, citing the company's royalty-focused business model and diversified portfolio as key drivers of continued earnings growth. Ligand provides capital and technology to drug and medical device developers in exchange for royalties, creating a portfolio of more than 100 commercial and development-stage assets that generate high-margin returns.

Solid pharma stocks offer promising upside opportunities. This particular play is eyeing an entry as earnings surge.

Buying a stock is easy, but buying the right stock without a good strategy is incredibly hard. Here are five top-performing stocks to buy now or put on a watchlist.